ULOQ [Study As­sess­ment]

posted by Anand – India, 2017-10-30 07:38 (2749 d 14:26 ago) – Posting: # 17945
Views: 10,351

Dear All,

Request to clarify,

In our Pivotal BE Study ULOQ was observed, whether we should exclude from PK?
After Dilution also it found ULOQ.
Method should be redeveloped or revalidated?
If included,What justification we should provide to Regulatory Agency?

Thanks in advance.

Regards,
A.A


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
132 visitors (0 registered, 132 guests [including 10 identified bots]).
Forum time: 23:04 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5